EQUALY sa.

Equaly is a discovery-stage biotechnology company, dedicated to leverage the role of a newly discovered type of Natural Killer T (“NKT”) cells to propose an innovative immunological approach to fight and eliminate tumour cells. Based on a newly discovered population of NKT lymphocytes, that can be activated by specific antigen through the same mechanism for everyone, allowing allogenic applications, Equaly develops innovative therapies that have the potential to revolutionise the treatment of cancers by offering a safer, more effective, and more affordable option than current therapies. Using the dynamic of the very same NKT cells, Equaly also develops non-immunogenic versions of existing Enzyme Replacement Therapies against metabolic orphan diseases.